RZLT Stock Summary and Trading Ideas (Rezolute - Common (Nv) | NASDAQ:RZLT)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

Rezolute - Common (Nv) trades on the NASDAQ stock market under the symbol RZLT.

As of November 6, 2026, RZLT stock price climbed to $3.88 with 1,458,418 million shares trading.

RZLT has a beta of 1.39, meaning it tends to be more sensitive to market movements. RZLT has a correlation of 0.01 to the broad based SPY ETF.

RZLT has a market cap of $375.28 million. This is considered a Small Cap stock.

In the last 3 years, RZLT traded as high as $11.46 and as low as $.72.

The top ETF exchange traded funds that RZLT belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

RZLT has underperformed the market in the last year with a return of -59.6%, while the SPY ETF gained +10.8%. In the last 3 month period, RZLT fell short of the market, returning -17.4%, while SPY returned -4.1%. However, in the most recent 2 weeks RZLT has outperformed the stock market by returning +0.6%, while SPY returned -3.2%.

RZLT support price is $3.45 and resistance is $3.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RZLT shares will trade within this expected range on the day.